Waverton Investment Management Ltd lifted its holdings in Becton Dickinson and Co (NYSE:BDX) by 9.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 432,388 shares of the medical instruments supplier’s stock after buying an additional 35,776 shares during the quarter. Becton Dickinson and comprises 5.4% of Waverton Investment Management Ltd’s portfolio, making the stock its 6th biggest holding. Waverton Investment Management Ltd’s holdings in Becton Dickinson and were worth $92,557,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Becton Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares during the last quarter. Harfst & Associates Inc. boosted its stake in Becton Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 221 shares during the last quarter. Harvest Fund Management Co. Ltd boosted its stake in Becton Dickinson and by 82.8% during the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after buying an additional 338 shares during the last quarter. Acrospire Investment Management LLC boosted its stake in Becton Dickinson and by 259.7% during the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock valued at $162,000 after buying an additional 600 shares during the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in Becton Dickinson and during the third quarter valued at approximately $191,000. 75.53% of the stock is owned by hedge funds and other institutional investors.

Shares of Becton Dickinson and Co (NYSE:BDX) traded up $5.02 during midday trading on Wednesday, reaching $226.42. The company’s stock had a trading volume of 1,387,200 shares, compared to its average volume of 1,719,833. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. The company has a market cap of $51,500.00, a PE ratio of 48.69, a PEG ratio of 1.70 and a beta of 1.07. Becton Dickinson and Co has a 1-year low of $168.37 and a 1-year high of $229.68.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.12 EPS. analysts forecast that Becton Dickinson and Co will post 10.89 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 8th were given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.32%. The ex-dividend date of this dividend was Thursday, December 7th. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio (DPR) is 64.52%.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Evercore ISI began coverage on Becton Dickinson and in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price target on the stock. Citigroup upgraded Becton Dickinson and from a “sell” rating to a “neutral” rating in a report on Friday, January 5th. KeyCorp began coverage on Becton Dickinson and in a report on Friday, January 5th. They set an “overweight” rating and a $260.00 price objective on the stock. Finally, Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the stock a “buy” rating in a report on Friday, December 29th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $230.20.

ILLEGAL ACTIVITY WARNING: “Becton Dickinson and Co (BDX) is Waverton Investment Management Ltd’s 6th Largest Position” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/becton-dickinson-and-co-bdx-is-waverton-investment-management-ltds-6th-largest-position/1801607.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.